Association of progression-free survival and overall response rate with overall survival in first-line randomized trials of immune checkpoint inhibitor–based regimens for metastatic non–small cell lung cancer (NSCLC): An FDA pooled analysis.

Authors

Bernardo Haddock Lobo Goulart

U.S. Food & Drug Administration, Silver Spring, MD

Bernardo Haddock Lobo Goulart , Sirisha Mushti , Somak Chatterjee , Erin A. Larkins , Martha Boeri Donoghue , Shenghui Tang , Richard Pazdur , Pallavi Shruti Mishra-Kalyani , Julia A. Beaver , Harpreet Singh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

First Author: Luis G. Paz-Ares

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.

First Author: Jie Wang

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.

First Author: Elizabeth Jimenez Aguilar

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.

First Author: Nashat Gabrail